Lack of evidence for increased inhibitor incidence in patients switched from plasma-derived to recombinant factor VIII.
De novo inhibitor development is a rare event in PTPs switched from pdFVIII to rFVIII. Based on previously published data of clinical studies a change in FVIII product is unlikely to provoke inhibitor formation.